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Abstract 28 
Plasmodium vivax is the major cause of human malaria in the Americas. How P. vivax 29 
infection can lead to poor clinical outcomes, despite low peripheral parasitaemia remains a 30 
matter of intense debate. Estimation of total P. vivax biomass based on circulating markers 31 
indicates existence of a predominant parasite population outside of circulation. In this study 32 
we investigate associations between both peripheral and total parasite biomass and host 33 
response in vivax malaria. We analysed parasite and host signatures in a cohort of 34 
uncomplicated vivax malaria patients from Manaus, Brazil, combining clinical and parasite 35 
parameters, multiplexed analysis of host responses and ex vivo assays. Patterns of clinical 36 
features, parasite burden and host signatures measured in plasma across the patient cohort 37 
were highly heterogenous. Further data deconvolution revealed two patient clusters, here 38 
termed Vivax
low
 and Vivax
high
. These patient subgroups were defined based on differences in 39 
total parasite biomass but not peripheral parasitaemia. Overall Vivax
low
 patients clustered 40 
with healthy donors and Vivax
high
 patients showed more profound alterations in 41 
haematological parameters, endothelial cell (EC) activation and glycocalyx breakdown and 42 
levels of cytokines regulating different haematopoiesis pathways compared to Vivax
low
. 43 
Vivax
high
 patients presented more severe thrombocytopenia and lymphopenia, along with 44 
enrichment of neutrophils in the peripheral blood and increased neutrophil-to-lymphocyte 45 
ratio (NLCR).  When patients’ signatures were combined, high association of  total parasite 46 
biomass with a subset of markers of EC activation, thrombocytopenia and lymphopenia 47 
severity was observed. Finally, machine learning models defined a combination of host 48 
parameters measured in the circulation that could predict the extent of parasite infection 49 
outside of circulation. Altogether, our data show that total parasite biomass is a better 50 
predictor of perturbations in host homeostasis in P. vivax patients than peripheral 51 
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parasitaemia. This supports the emerging paradigm of a P. vivax tissue reservoir, in particular 52 
in the hematopoietic niche of bone marrow and spleen. 53 
Keywords: Plasmodium vivax, malaria parasite, total biomass, tissue infection, 54 
endothelial activation, haematopoiesis. 55 
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Introduction 77 
Malaria remains a heavy burden across endemic regions worldwide. In 2018 P. vivax 78 
infection accounted for 41% of all malaria cases outside of Sub-Saharan Africa, with a total 79 
of 6.5 million cases and more than 2 billion people in 90 countries at risk 
1
. There are 80 
concerns that P. vivax elimination will be significantly more difficult than P. falciparum, as 81 
the current measures for malaria control are less effective for P. vivax than for P. falciparum, 82 
with the elimination of the former presenting a major challenge in areas that successfully 83 
reduced P. falciparum burden. This persistence is due to some unique biological features 84 
complicating treatment and elimination, including low peripheral parasitaemia and presence 85 
of dormant liver stages (hypnozoites) which relapse weeks or months after blood infection 86 
has been cleared.  87 
P. vivax infection is associated with low peripheral parasitaemia (< 2%), as a result of 88 
a strict host cell tropism to immature reticulocytes 
2,3
 that are exceedingly rare in peripheral 89 
blood (< 2%) but highly prevalent in the hematopoietic niche of BM and spleen 
4,5
. Because 90 
of limited microvascular adherence in vivo and endothelial cell (EC) binding in vitro 
6,7
, it 91 
was generally assumed that peripheral parasitaemia reflects the majority of P. vivax parasites 92 
during infection. However, discrepancy of parasite biomass based on systemic biomarkers 93 
such as Plasmodium lactate dehydrogenase (pLDH) compared to peripheral parasitaemia 94 
supports existence of a major P. vivax reservoir outside of circulation, in particular in patients 95 
with complicated outcomes 
8
. In support of this hypothesis, studies have demonstrated that 96 
late asexual blood stage P. vivax parasites (i.e., schizonts) are capable of cytoadhering to 97 
endothelial host receptors 
9,10
 and present at reduced abundance compared to the other blood 98 
stages in the blood of P. vivax patients 
11,12
. In experimentally infected non-human primates 99 
(NHPs), a significant enrichment of sexual stages (gametocytes) and schizonts in bone 100 
marrow sinusoids and parenchyma has been observed 
11
, supporting previous evidence from 101 
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multiple case reports that identified P. vivax in bone marrow and spleen 
13-20
. A series of 102 
recent studies in acute and chronic human P. vivax infection have meanwhile provided direct 103 
evidence that bone marrow and spleen represent the major reservoir of parasite biomass in P. 104 
vivax infection 
17,20-22
. 105 
P. vivax parasites can elicit a potent host response, including inflammation and 106 
endothelial cell (EC) activation, and cause severe and fatal manifestations at significantly 107 
lower peripheral parasitaemia than the more virulent species, P. falciparum 
8,23
. However, the 108 
pathogenic mechanisms underlying these alterations in host homeostasis and their 109 
relationship with P. vivax biomass are not fully understood 
24-27
.   110 
Here we systematically investigated host responses in a cross-sectional cohort of 111 
uncomplicated P. vivax patients from Manaus, in the Brazilian Amazon region. Our analysis 112 
revealed an association between alterations in host homeostasis, including EC activation, 113 
damage and haematological disturbances, such as thrombocytopenia, lymphopenia and 114 
increased neutrophils turnover, with total parasite biomass but not peripheral parasitaemia. 115 
These findings are in line with the emerging paradigm of a clinically relevant parasite 116 
reservoir outside of circulation and merit systematic investigations of this reservoir in vivax 117 
malaria. 118 
 119 
 120 
 121 
 122 
 123 
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Results 125 
Uncomplicated P. vivax patients present with haematological changes   126 
We have conducted a cross-sectional study with uncomplicated P. vivax malaria patients seen 127 
at FMT-HVD in Manaus, Brazil. We included 79 adult patients (median age of 36 years) with 128 
confirmed P. vivax infection (smear and PCR positive) and 34 age- and sex-matched 129 
uninfected healthy donors (controls) (Table 1).  All individuals within the study including 130 
controls were from the State of Amazonas, in the Amazon region of Brazil. Blood was 131 
collected at enrolment for determination of haematological parameters, peripheral 132 
parasitaemia by Giemsa staining of blood smears and PCR to determine genome copy 133 
numbers. Preparation of poor platelet plasma (PPP) was done within 15 minutes of sampling. 134 
The median peripheral parasitemia was 4,290 infected red blood cells (iRBCs)/L of blood 135 
(25-75 interquartile range 1,860-6,620 parasites/L) and parasite load of 26,642 copies of 18s 136 
RNA/L (25-75 interquartile range 9,253-522,297). We also measured total parasite biomass 137 
independently of peripheral parasitaemia by quantifying levels of P. vivax lactate 138 
dehydrogenase (PvLDH) in plasma (Table 1).  139 
Analysis of haematological parameters revealed significantly reduced haemoglobin 140 
levels and haematocrit across P. vivax patients compared to controls, with anaemia in 38% of 141 
the patients (Figure 1A). Similarly, leukocyte numbers were significantly decreased (Mean ± 142 
SD: 4.36±1.74 x10
3
/L vs. 5.72±1.34 x10
3
/L, p=0.0004), with 54.5% of the patients 143 
presenting with leukopenia (defined as a leukocyte count < 4000 cells/L). In contrast, 144 
neutrophil counts were not significantly different, and only 8.3% of P. vivax patients were 145 
presenting with neutropenia (neutrophil counts < 1,500 cells/L) (Figure 1B). Other myeloid 146 
cell populations however, such as monocytes, basophils and eosinophils (MXD), were 147 
significantly reduced. We also observed a significant reduction in lymphocyte and platelet 148 
counts in this cohort (Figure 1C), with 80% presenting with lymphopenia (lymphocyte 149 
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counts < 1,000 cells/L) and 87% with thrombocytopenia (platelet counts < 150,000 150 
cells/L), many of them with severely reduced levels (Figure 1C). Alterations in platelet 151 
counts were accompanied by the release of mega platelets in the peripheral circulation as a 152 
significant increase on mean platelet volume was observed (Figure 1C). 153 
In summary, patients in our cohort presented with a wide range of parasitaemia and 154 
uncomplicated clinical signs of P. vivax infection at medical consultation. However, 155 
significant haematological abnormalities were present in the majority of patients during early 156 
onset of disease, in line with previous findings 
8,24,28-32
.  157 
 158 
Unsupervised clustering reveals two P. vivax patient subgroups that differ in parasite 159 
biomass: Vivax
high
 vs Vivax
low
 160 
To determine whether the observed changes were associated with specific host signatures, in 161 
particular circulating biomarkers of haematological and endothelial changes, we applied a 162 
multiplexed microbead-based immunoassay (Luminex) in a representative subset of 31 P. 163 
vivax patients and 9 controls, as explained in the Methods section (Figure 1-figure 164 
supplement 1). We selected a series of circulating biomarkers associated with 165 
haematological changes, including cytokines altering thrombopoiesis (TPO and IL-11), 166 
myelopoiesis and lymphopoiesis (TNF-, IL-1, IL-1, IL-6, IL-8, G-CSF) 
33-35
. In addition, 167 
we selected markers of endothelial cell (EC) and platelet activation, coagulation (ICAM-1, 168 
VCAM-1, E-selectin, P-selectin, Angiopoietin-1 and -2, CD40L, VWF-A2, ADAMTS13, 169 
PAI-1, CXCL4, CXCL7) and EC glycocalyx breakdown (Syndecan-1).  170 
We observed significant upregulation of multiple cytokines associated with 171 
haematological changes in the P. vivax patients compared to control (Table 1). In addition, 172 
patient samples exhibited a strong phenotype of increased EC activation, glycocalyx 173 
breakdown and coagulation. The high interquartile range in parasitaemia and host signatures 174 
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(Table 1) suggested a heterogenous phenotype across the patient population. In order to 175 
identify possible stratification of patients into distinct subgroups, we further analysed the 176 
clinical data (Figure 1), parasite parameters and Luminex data (Table 1) from the same 31 P. 177 
vivax patients and 9 controls as above. After z-score normalization, Principal Component 178 
Analysis (PCA) was performed for data dimensionality reduction, considering the large 179 
number of variables in our dataset. Next, we ran K-means Clustering (k) followed by 180 
bootstrapping (Figure 2A, B, Figure 2-figure supplement 1, Figure 2-figure supplement 181 
2, Figure 2- figure supplement 2-source data 1) to identify possible subclusters of 182 
individuals. This analysis revealed consistent separation of samples into 2 clusters, one of 183 
them including all controls (Cluster 1a) and a subset of 14 patient samples (Cluster 1b) and a 184 
second one representing the remaining 17 patient samples (Cluster 2) (Figure 2A, B). In 185 
order to visualize covariables of the observed patient distribution (PCA) and clustering (K-186 
means), we plotted the correlation (loading score) of each input variable with a principal 187 
component (Figure 2C, Figure 2-source data 1). This analysis demonstrated covariation of 188 
lymphopenia and thrombocytopenia on one hand, and markers of EC changes, platelet 189 
production, activation and parasite parameters (PvLDH and peripheral parasitemia) on the 190 
other hand as major contributors to the principal components (Figures 2C). Direct 191 
comparison of the 2 patient subgroups revealed significant higher total parasite biomass but 192 
not peripheral parasitaemia or parasite load (Figure 3A). In agreement with previous findings 193 
8,36,37
, z-score comparison further demonstrated that total parasite biomass was higher than 194 
and not correlated with peripheral parasitaemia levels or parasite load, in particular in 195 
patients of cluster 2 (Figure 3B, C). In addition, PvLDH was the input parasite variable with 196 
the highest loading score (correlation = 0.59) and lowest p-value (0.0000917) in the first PC 197 
dimension when compared with peripheral parasitaemia and parasite load (Figure 2C, 198 
Figure 2-source data 1). Indeed, using a best-fit classification tree model and a random 199 
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forest machine learning model defining k-means clusters as categorical outcome, PvLDH is 200 
the best parasite predictor attribute segregating patients into clusters 1b and 2 (Figure 3D, E). 201 
After both models were trained in a set of 30 individuals, randomly selected by the training 202 
algorithm set, they were tested in the 10 remaining individuals, where all cluster 1a (control) 203 
individuals and 80% of P. vivax patients were correctly classified in either cluster 1b or 204 
cluster 2. Based on these observations we designated cluster 1a as Control cluster 205 
(representing the healthy donors), cluster 1b as Vivax
low
 (representing patients with low P. 206 
vivax biomass) and cluster 2 as Vivax
high
 (representing patients with high P. vivax biomass).  207 
 208 
Different levels of haematological alterations between Vivax
high
 and Vivax
low
 patients 209 
The three clusters were not significantly different in patient age (median: 33; IQ 25-75: 22-210 
57), gender (80% male; 20% female in each cluster), average days of symptoms when 211 
samples were collected, haemoglobin levels, haematocrit or RBC counts, indicating that these 212 
parameters are not confounders accounting for the differences observed between the clusters 213 
(Figure 4A). However, systematic analysis of haematological parameters between Vivax
high 
214 
and
 
Vivax
low
 patients revealed significant differences. Vivax
high
 patients showed a more 215 
intense reduction in platelet counts when compared to Vivax
low
 patients (Vivax
high
 63,000 ± 216 
6,413 vs Vivax
low
: 100,700 ± 9,381; p = 0.002), with a higher frequency of patients with 217 
severe thrombocytopenia (Vivax
high
 47% vs Vivax
low
 8%) (Figure 4B). Although not 218 
significant, there was a trend in the reduction of lymphocyte counts in Vivax
high
 patients 219 
when compared to Vivax
low
, with 88% of Vivax
high
 patients presenting lymphopenia versus 220 
64% in Vivax
low
 patients. In addition, we observed a 4-fold increase in the frequency of 221 
patients with severe lymphopenia in the Vivax
high
 cluster compared to Vivax
low
 patients 222 
(Figure 4B). While there was no change in the number of circulating neutrophils in the 223 
different clusters of individuals, mixed cell counts (MXD), a parameter representing 224 
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monocytes, basophils and eosinophils numbers, was significantly reduced in Vivax
high
 225 
patients. As a result, there was a significant enrichment of neutrophils in the leukocyte 226 
fraction in the blood of Vivax
high
 patients as well as a higher Neutrophil:Lymphocyte count 227 
ratio (NLCR) (Figure 4B). 228 
 In parallel to more severe thrombocytopenia in Vivax
high
 patients, plasma levels of 229 
cytokines inducing megakaryocytic differentiation in the bone marrow (BM), thrombopoietin 230 
(TPO) and IL-11, were significantly increased in this cluster (Figure 4C, Figure 4-figure 231 
supplement 1). In accordance with the pattern of immune cell fractions in the peripheral 232 
blood of P. vivax
 
patients, the Vivax
high
 cluster showed a significant increase in the levels of 233 
pro-inflammatory cytokines associated with induction of myeloid-biased haematopoietic 234 
stem cell (HSC) differentiation and inhibition of lymphopoiesis in BM (e.g., TNF-, IL-1, 235 
IL-1, IL-6, IL-8; Figures 4C, Figure 4-figure supplement 1) 
33-35
. In addition, Vivax
high
 236 
patients had increased circulating levels of G-CSF, a major mediator of HSC-biased 237 
myelopoiesis and the neutrophil activation marker, L-Selectin (Figures 4C, Figure 4-figure 238 
supplement 1) 
38-40
. Together, these Luminex data support the haematological measurements, 239 
suggesting that a compensatory response is mounted in the BM to counterbalance the massive 240 
decrease of platelets in periphery. Upregulation of cytokines inducing myelopoiesis, while 241 
inhibiting lymphopoiesis 
33-35
, might also explain the decrease of lymphocyte counts and 242 
enrichment of activated neutrophils in the peripheral circulation of P. vivax patients. 243 
 244 
Elevated circulating markers of EC activation and damage in Vivax
high
 compared to 245 
Vivax
low
 patients  246 
Patient clustering indicated that Vivax
high
 patients have increased levels of EC markers in the 247 
plasma compared to Vivax
low
 patients (Figure 2C). Previous studies indicate that EC 248 
activation and damage might contribute to thrombocytopenia and inducing hematopoiesis, 249 
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resulting in HSC differentiation directed towards myelopoiesis 
24,28,29,33-35,41-43
. In our cohort, 250 
circulating levels of EC adhesion molecules (ICAM-1, VCAM-1, E-selectin and P-selectin) 251 
and other EC activation markers and procoagulant molecules (Ang-2, VWF-A2, CD40L and 252 
PAI-1) were significantly increased in the plasma of Vivax
high
 patients compared to Vivax
low
 253 
patients and healthy controls (Figures 5A, Figure 5-figure supplement 1A, B). Likewise, 254 
Syndecan-1, a marker of EC glycocalyx breakdown (i.e., damage of EC plasma membrane) 255 
44,45
, was significantly increased Vivax
high
 but not in Vivax
low
 patients (Figures 5A, Figure 5-256 
figure supplement 1C). 257 
To independently test whether host factors and/or parasite products present in the 258 
plasma of the different patient groups can directly induce changes in ECs, we stimulated 259 
primary human umbilical vein endothelial cells (HUVECs) with pools of plasma from either 260 
Vivax
high 
patients, Vivax
low
 patients, or healthy controls. These experiments demonstrated 261 
that only pooled plasma from Vivax
high
 patients induces significant transcriptional 262 
upregulation of EC activation markers ICAM-1, IL-1, IL-8 along with downregulation of 263 
Ang-1, ADAMTS13 and NOS3 (eNOS) in HUVECs (Figure 5B, Figure 5-figure supplement 264 
1D). In contrast, expression of Syndecan-1 and VEGF, two indicators of vascular damage, 265 
was not affected by either treatment (Figure 5B, Figure 5-figure supplement 1D). 266 
Similarly, electric cell-substrate impedance sensing (ECIS) assays did not detect differences 267 
in functional perturbations in the endothelial cellular monolayer upon incubation with P. 268 
vivax pooled plasma when compared to control pooled plasma (Figure 5C).  In contrast, flow 269 
cytometry and immunofluorescence assays performed with stimulated HUVECs revealed 270 
increased prevalence and protein expression levels of EC activation markers ICAM-1 and 271 
VCAM-1 upon exposure with Vivax
high
 pooled plasma (Figure 5D, Figure 5-figure 272 
supplement 1E), in support of qRT-PCR data. These data indicate that local EC activation, 273 
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mediated by direct or indirect interactions with parasitized RBCs, can be measured 274 
systemically. 275 
 276 
Indirect evidence for parasite-induced changes in deep tissues  277 
To further investigate the interplay between host biomarkers and associated cellular 278 
responses as well as parasite parameters we constructed a network of interactions based on 279 
Pearson correlations with absolute correlation coefficient above 0.5 and p-value < 0.05 280 
(Figure 6A). In addition, we also performed hierarchical clustering on matrices of Pearson 281 
correlations (p-value < 0.01) with selected modules of parasite and host parameters (Figure 282 
6B). Data from Vivax
low
 and Vivax
high
 patient subgroups were combined for this analysis as 283 
they similarly contribute to the associations we found so far (Figure 6-figure supplement 1).  284 
Similar to a previous study with P. vivax patients and healthy donors from an endemic area in 285 
Brazil 
46
, our analysis revealed a dense network of interactions with homogenous and 286 
centralized topology among the biomarkers in healthy donors (Figure 6A, Supplementary 287 
File 1). The network topology is drastically altered in symptomatic P. vivax patients, largely 288 
due to the introduction of parasite parameters in the patient graph (Figure 6A, 289 
Supplementary File 1). The network analysis revealed a decentralized topology, lower 290 
complexity and connectivity between the edges with data from P. vivax patients compared to 291 
the highly dense, homogenous and centralized network graph of healthy donors (91 edges vs 292 
166 edges, respectively). Of note, the network pattern described in our study is similar to 293 
protein-protein associated networks described previously in P. vivax malaria and in other 294 
clinical contexts
46,47
. Interestingly, due to its decentralized and heterogenous patterns of 295 
interactions, the network graph of P. vivax patients is separated into three modules of strong 296 
interactions, with closely related biological functions. Module 1 is formed by markers of EC 297 
activation and damage, together with lymphocyte, platelet and neutrophil counts in addition 298 
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to the megakaryocyte differentiation inducing cytokines (TPO and IL-11) (Figure 6A). In 299 
support of the role of EC activation and damage in the haematological changes observed in 300 
this cohort, hierarchical clustering revealed a positive correlation between adhesion 301 
molecules VCAM-1 and E-selectin and EC glycocalyx breakdown (Syndecan-1) (Figure 302 
6B). In addition, VCAM-1, E-selectin, Ang-2 and VWF-A2, and Syndecan-1 are negatively 303 
correlated with platelet and lymphocyte counts, while ICAM-1 is positively correlated with 304 
neutrophil counts (Figures 6A, B). Module 2 is formed by proinflammatory cytokines with 305 
myelopoiesis inducing effects and molecules associated with platelet activation and 306 
coagulation cascades (Figures 6A, B). Interestingly, EC activation markers and Syndecan-1 307 
(EC damage) from module 1 also display positive correlations with myelopoiesis-inducing 308 
cytokines from module 2 (Figure 6B). Finally, module 3 is formed by Ang-2 and the 309 
proinflammatory cytokine IL-1 negatively associated with haemoglobin, haematocrit and 310 
RBC numbers (anemia markers) (Figures 6A, B). Most notably, PvLDH connects the two 311 
main functional modules 1 and 2 (Figures 6A, B). Accordingly with Figures 2 and 6A,B, the 312 
biological significance of total parasite biomass, but not peripheral parasitaemia or parasite 313 
load, in affecting host response is also corroborated by the high significant and positive 314 
associations of PvLDH with multiple host parameters, including Syndecan-1 (EC damage), 315 
VCAM-1, VWF (EC activation and platelet pooling), and IL-6, IL-8, TNF- (inflammation 316 
and myelopoiesis inducing cytokines) (Figure 6C). Meanwhile, platelet, lymphocyte and 317 
neutrophil counts are negatively correlated with high significance (p-value < 0.0001) with 318 
total parasite biomass, but not with peripheral parasitaemia or parasite load (Figure 6C). The 319 
association between endothelial activation, Syndecan-1 and parasite biomass (PvLDH) 320 
indicates a positive feedback loop between glycocalyx breakdown, activation of endothelial 321 
receptors such as ICAM-1and VCAM-1 and parasite accumulation in deep tissues
9,12
. Similar 322 
to Figure 2E, application of a best-fit classification tree model demonstrated that Syndecan-1, 323 
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IL-6 and platelet counts are the most dominant predictor attributes capable to classify P. 324 
vivax patients based on total parasite biomass levels (Figure 6D). Using this model all P. 325 
vivax patients were correctly classified in either low (Vivax
low
) or high (Vivax
high
) total 326 
parasite biomass (PvLDH). In turn, PvLDH is a relevant predictor attribute (high information 327 
gain) in predicting thrombocytopenia severity and it is associated with increased severity of 328 
thrombocytopenia and lymphopenia in our cohort (Figure 6-figure supplement 2, Figure 6-329 
figure supplement 3). Together, these data further support the hypothesis that a parasite 330 
population outside of circulation, as represented by total parasite biomass, is driving the host 331 
response including EC activation and damage as well as haematological disturbances (i.e., 332 
lymphopenia, thrombocytopenia and anaemia) in P. vivax patients (Figure 6-figure 333 
supplement 2, Figure 6-figure supplement 3).  334 
 335 
Discussion 336 
In this study, we performed a comprehensive analysis of host and parasite signatures detected 337 
in the plasma of a cross-sectional cohort of uncomplicated P. vivax malaria.  Initial analysis 338 
of a series of circulating host biomarkers revealed significant levels of thrombocytopenia, 339 
lymphopenia and anaemia, as well as EC activation and damage across P. vivax patients 340 
compared to healthy controls. Deconvolution of heterogeneity across patients revealed two 341 
patient subgroups (Vivax
high
 and Vivax
low
) characterized by differences in total parasite 342 
biomass (based on circulating PvLDH levels) but not peripheral parasitaemia (based on blood 343 
smears).  We observed a significant correlation between total parasite biomass (but not 344 
peripheral parasitaemia) and systemic levels of markers of EC activation and damage and 345 
hematopoietic perturbations. In addition, by applying a supervised machine learning tree-346 
structured model, we were able to associate EC damage and thrombocytopenia with parasite 347 
biomass. In agreement with a previous study
8,37
 our observations further suggest that total 348 
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parasite biomass as measured by PvLDH is a better predictor of P. vivax host responses and 349 
pathogenesis than peripheral parasitaemia. Furthermore, these findings support the emerging 350 
paradigm of a major P. vivax parasite reservoir outside of circulation, in particular in the 351 
haematopoietic niche of bone marrow and spleen 
37
. 352 
The existence of a significant P. vivax reservoir outside of circulation was first 353 
predicted by disproportionately high PvLDH levels in peripheral circulation compared to 354 
parasitemia by blood smear (in particular in patients with complicated outcomes), and by 355 
modelling using experimental P. cynomolgy infections in non-human primates
8,36
. Recent 356 
studies provide direct evidence that bone marrow and spleen represent the major reservoir of 357 
parasite biomass in P. vivax infection
11,17,20-22
.  PvLDH is produced by viable or recently 358 
killed parasites and hence considered a proxy for ongoing rather than past infection
8,48
. 359 
PvLDH antigen capture ELISA established a direct relationship between pLDH levels and P. 360 
vivax parasitemia in ex vivo experiments, demonstrating that pLDH reflects total P. vivax 361 
parasite biomass
48
. Our study further explores the relevance of PvLDH as a prognostic 362 
marker of host perturbations and disease severity, with a particular focus on markers of 363 
changes in the hematopoietic niches of bone marrow and spleen.  A major observation in the 364 
network graph of P. vivax patients is the central position of the total parasite biomass marker 365 
PvLDH, due to its equally strong interactions with the two main functional modules 1 and 2. 366 
Given that the hematopoietic niches of the BM and the spleen are the major reservoir of 367 
parasite biomass, interactions of PvLDH with these two main modules indicate an interplay 368 
between parasite infection in these niches and endothelial activation/damage as well as the 369 
proinflammatory response that results in myeloid-biased differentiation, thrombocytopenia 370 
and lymphopenia. Furthermore, the highly significant and positive associations between 371 
endothelial activation, Syndecan-1 and parasite biomass (PvLDH) indicates a positive 372 
feedback loop between glycocalyx breakdown, activation of endothelial receptors such as 373 
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ICAM-1and VCAM-1 and parasite accumulation in deep tissues. Vivax
High 
patients show 374 
higher plasma levels of all these markers. Consistent with previous reports 
44,49
, we propose 375 
that elevated EC activation and glycocalyx damage increases the exposure of adhesion 376 
molecules, which in turn favours endothelial cytoadherence of P. vivax-infected RBCs, in 377 
particular in the splenic red pulp cords and in the BM 
21,50-52
. Accordingly, application of a 378 
best-fit classification tree model identifies Syndecan-1 is a putative host biomarker (EC 379 
glycocalyx breakdown marker) predicting total parasite biomass in P. vivax patients. We 380 
hypothesise that elevated endothelial activation and damage in Vivax
High
 patients results in 381 
increased cytoadherence of P. vivax iRBCs and hence accumulation and growth in deep 382 
tissues, thus reducing the fraction of the parasite biomass in circulation.    383 
In contrast to P. falciparum-infected individuals, a wide range of complicated clinical 384 
syndromes occurs in P. vivax patients even at low or subpatent parasitemia
53
 – thus indicating 385 
that peripheral parasitemia is a poor predictor of clinical outcomes. Two lines of evidence 386 
support our conclusion that severity of infection is dependent on parasite biomass instead. 387 
First, the discrepancy between PvLDH levels and peripheral parasitaemia determined by 388 
blood smears is more evident in P. vivax-infected patients with complicated outcomes: the 389 
ratio of plasma pLDH to peripheral parasitaemia is 6-fold higher than in non-severe patients. 390 
The same comparison between severe and non-severe P. falciparum patients reveals only a 391 
1.4-fold difference
8
. Second, although thrombocytopenia and lymphopenia are not included 392 
in the World Health Organization (WHO) criteria for defining severe malaria, it has been 393 
associated with severe manifestations and the need for blood and platelet transfusions in 394 
severe vivax malaria. This points out their clinical relevance in malaria diagnosis and 395 
treatment 
24,25,54-56
, suggesting that these haematological complications could be explored as 396 
markers of severity for this species. Both severe thrombocytopenia and lymphopenia were 397 
more frequent in patients in the Cluster 2 (Vivax
high
) in our study. By integrating these 398 
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clinical perturbations with host biomarker measurements and parasite parameters, we 399 
demonstrated the high attribute value of total parasite biomass in predicting the severity of 400 
thrombocytopenia and lymphopenia and highly significant correlations with endothelial 401 
activation, glycocalyx breakdown and other markers of inflammation. 402 
 Thrombocytopenia, lymphopenia and anaemia are the most frequent P. vivax and P. 403 
falciparum associated haematological complications 
24-27
.  In our cohort, 34%, 85% and 87% 404 
of patients exhibited anaemia, lymphopenia and thrombocytopenia, respectively. Various 405 
mechanisms have been proposed to explain the damage or excessive removal of platelets in 406 
P. vivax infection, including oxidative stress, platelet phagocytosis, IgG binding to platelet-407 
bound malaria antigens, spleen pooling, or increased circulating nucleic acids levels 
24,25,55,57
. 408 
EC activation and damage also play a role in intravascular platelet agglutination and 409 
increased platelet clearance from the circulation 
31,32
. Our data also demonstrate that 410 
thrombocytopenia is associated with an increase in IL-1, IL-6, IL-8, IL-10 and TNF-. We 411 
also observed elevated levels of cytokines inducing megakaryocyte differentiation, TPO and 412 
IL-11, suggesting that a compensatory response is mounted in the BM to counterbalance the 413 
massive decrease of platelets in the periphery. In contrast, the relatively large drop in 414 
peripheral lymphocyte numbers we observed in the P. vivax patients is likely non-specific 415 
effect, e.g. pooling in the enlarged spleen rather than a response by Plasmodium-specific 416 
lymphocytes 
58
. Corroborating the potential role of total parasite biomass, rather than 417 
peripheral parasitaemia, in haematological disturbances (i.e., lymphopenia, thrombocytopenia 418 
and anaemia), Figures S7 and S8 show that total parasite biomass increases accordingly with 419 
thrombocytopenia and lymphopenia severity. Patients with severe thrombocytopenia also 420 
show more severe leukopenia, lymphopenia and mega platelets (higher MPV). In addition, 421 
plasma levels of cytokines, such as TNF-, IL1-, IL-8, IL-10; EC activation/damage 422 
markers, VCAM-1, E-selectin, VWF-A2, Ang-2, Ang-2:Ang1 ratio; Syndecan-1; 423 
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thrombopoiesis-inducing cytokines, TPO and IL-11; platelet activation marker, CD40L and 424 
neutrophil activation marker, L-selectin, follow the increase in thrombocytopenia severity 425 
(Figure 6-figure supplement 2). A similar pattern is observed when stratifying patients 426 
based on lymphopenia severity (Figure 6-figure supplement 3).  Interestingly, a tree-427 
structured model demonstrated that PvLDH, along with VCAM-1 and Syndecan-1, is a 428 
relevant predictor attribute (high information gain) in predicting thrombocytopenia severity 429 
in our cohort (Figure 6-figure supplement 2). 430 
 Our data support previous studies suggesting a role for endothelial cell (EC) 431 
activation and damage in increased leukocyte adhesion, intravascular platelet agglutination 432 
with increased platelet clearance from the circulation and skewing of haematopoiesis toward 433 
the myeloid lineage (likely at the expense of lymphopoiesis) in the BM 
28-30,33-35,41,42,45
. P. 434 
vivax elicits a stronger inflammatory response and more pronounced endothelial activation 435 
when compared with other Plasmodium infections with similar or higher peripheral 436 
parasitaemia 
23
, however the role of EC activation in P. vivax pathogenesis is not yet 437 
understood. Damage of the EC plasma membrane, as represented by glycocalyx breakdown, 438 
has been associated with poor prognostic outcome in P. falciparum 
44
, but there is no data 439 
available for P. vivax. In our cohort soluble EC activation biomarkers (e.g., ICAM-1, 440 
VCAM-1, E-selectin, Ang-2, CD40L, vWF-A2) and the EC damage product, Syndecan-1, are 441 
positively correlated with thrombocytopenia, lymphopenia, anaemia and neutrophil 442 
enrichment in the peripheral blood. In addition, these biomarkers are positively correlated 443 
with increased circulating levels of cytokines inducing megakaryocyte-differentiation (e.g., 444 
IL-11 and TPO) and with cytokines inducing myeloid-biased HSC differentiation (e.g., TNF-445 
, IL1-, IL6, IL-8 and G-CSF), suggesting both direct and indirect links between EC 446 
activation and damage and haematological perturbations. Total parasite biomass inducing EC 447 
activation might act synergistically with inflammatory changes potentially leading to splenic 448 
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platelet pooling and platelet clumping in the vasculature without DIC 
19,45,59
 . Likewise, 449 
increased activation-induced cell death (AICD) in T cells, splenic T-cell accumulation 
58
 or 450 
decreased lymphopoiesis due to myeloid-biased HSC differentiation induced by 451 
inflammatory cytokines and EC activation in the BM 
33,34,37
 might explain the severe 452 
lymphopenia and neutrophilia in vivax patients. Together such mechanisms could explain the 453 
link between parasite biomass and EC activation/damage with haematological changes 454 
observed in vivax patients that might contribute to pathogenesis and disease severity.  455 
In a second series of experiments, we performed ex vivo stimulation of HUVECs with the 456 
plasma of the P. vivax cohort demonstrating that the mixture of parasite and host factors can 457 
directly induce EC activation in absence of parasitized RBCs. Of note, functional 458 
differences between HUVECs and adult vascular endothelium, including lack of ABO 459 
blood group antigen expression, have been reported
60,61
 . Hence EC stimulation with 460 
patient plasma may be further evaluated using primary vascular ECs.  461 
 ECs are capable of responding to pathogens by sensing pathogen-associated 462 
molecular patterns (PAMPs) through pattern-recognition receptors (PRRs), which might play 463 
a key role in inducing EC activation when detecting P. vivax molecules enriched in the 464 
tissues where the parasite accumulates. ECs also express specific cytokine/chemokine 465 
receptors to detect proinflammatory signals released systemically or locally by activated 466 
immune cells in response to infection 
62,63
. As result, EC activation induces exocytosis of 467 
secretory granules known as Weibel–Palade bodies that leads to the release of Ang-2 and 468 
VWF, as well as transcriptional programs that activate expression of adhesion molecules such 469 
as ICAM-1, VCAM-1, E-selectin, and secreted cytokines and chemokines 
29,62,63
.  However, 470 
EC pathophysiology is complex, and changes represent a heterogenous spectrum ranging 471 
from simple perturbation to activation and even endothelial cell damage 
28
. Our Luminex data 472 
clearly confirm such heterogeneity in the spectrum of EC changes due to P. vivax infection, 473 
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with systemic increase of markers of EC activation and damage only detected in Vivax
high
 474 
patients.  The ex vivo data show that increased systemic host proinflammatory factors and/or 475 
parasite products can alter EC properties, including activation of adhesion molecules and 476 
proinflammatory cytokines and downregulation of ADAMTS13. In contrast, vascular 477 
integrity was not affected. These data indicate that systemic inflammatory responses in P. 478 
vivax patients can lead to local EC activation but not vascular damage, central events in 479 
malaria pathogenesis. It is likely that other circulating factors that we have not directly 480 
measured in our study are also contributing to EC activation and vascular permeability. In 481 
particular, extracellular vesicles (EV) originating from ECs, platelets, and RBCs are present 482 
during malaria infection and are known to modulate the host immune response to the 483 
parasite
52,64,65
 . In P. falciparum, infected RBCs release EVs containing immunogenic 484 
parasite antigens, that activate macrophages, induce neutrophil migration and alter 485 
endothelial barrier function
64,65
. In P. vivax, plasma-derived EVs from iRBCs are taken up by 486 
human spleen fibroblasts (hSFs). This event signals NF-kB translocation and upregulation of 487 
ICAM-1 expression, facilitating cytoadherence of P. vivax-infected reticulocytes
52
.  488 
 Although our study lacks longitudinal information, the findings might have clinical 489 
implications during and after treatment of vivax malaria. Several case reports demonstrate 490 
progressive clinical deterioration after commencement of treatment in P. vivax patients, 491 
associated with parasite killing that result in haemolysis of iRBCs and intravascular 492 
inflammation and oedema in response to the products released from these cells 
66-69
. Patients 493 
presenting with a strong host response during acute infection might therefore be at increased 494 
risk of deteriorating and developing severe symptoms after commencement of treatment 495 
(Figure 5-figure supplement 2).  Thus, identification of unique biological signatures in P. 496 
vivax patients might help to build rational approaches to the diagnosis, prognosis and 497 
individualized treatment to modulate the host response to vivax malaria. 498 
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 Altogether, our data indicate that changes in clinical parameters and biomarkers 499 
detected in the plasma of P. vivax patients are the result of both, systemic host responses and 500 
local infection in tissue reservoirs such as BM and spleen. Our analysis shows that measuring 501 
a combination of host parameters (e.g., Syndecan-1, IL-6, platelet levels) and total parasite 502 
biomass (PvLDH) could predict the extent of parasite infection outside of circulation. Our 503 
data also instigate future investigations of systemic signatures with parallel analysis focused 504 
on tissue responses, in particular in reservoirs such as the haematopoietic niche of BM and 505 
spleen, which has great potential to advance better diagnosis and treatment of P. vivax.  506 
 507 
Materials and Methods 508 
Key Resources Table 509 
Key Resources Table 
Reagent 
type 
(species) or 
resource 
Designation 
Source or 
reference 
Identifiers 
Additional 
information 
biological 
sample 
(Homo-
sapiens) 
Human 
umbilical 
vein 
endothelial 
cells 
(HUVEC) 
Hematology 
Center -
University of 
Campinas, 
Campinas, 
SP, Brazil 
  
Primary 
cells 
isolated 
from the 
umbilical 
vein. 
antibody 
ICAM-1 
(mouse 
monoclonal) 
 
 Abcam 
Cat. #ab2213; 
RRID: AB_302892 
Antibody 
clone MEM-
111 
IF (1:100) 
antibody 
VCAM-1 
(mouse 
monoclonal) 
 
 Abcam 
Cat. #ab212937; 
RRID: 
AB_2892824 
Antibody 
clone 1.4C3 
IF (1:500) 
FC (1:100) 
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antibody 
IgG1 isotype 
control 
(mouse 
monoclonal) 
 
 Dako 
Cat. #X0931; 
RRID: 
AB_2892825 
IF (1:10) 
antibody 
ICAM-1 
(mouse 
monoclonal) 
 Biolegend 
Cat. #322714; 
RRID:AB_535986 
Antibody 
clone 
HCD54 
FC (1:100) 
antibody 
pLDH Vivax-
specific 
(mouse 
monoclonal) 
Vista 
Diagnostics 
International 
LLC, WA, 
USA 
Cat. #3h8; 
RRID: 
AB_2892826 
Antibody 
clone 3h8 
ELISA 
(1g/mL) 
antibody 
pLDH 
detection 
antibody 
(goat 
monoclonal) 
Vista 
Diagnostics 
International 
LLC, WA, 
USA 
Cat. #6c9; 
RRID: 
AB_2892827 
Antibody 
clone 6c9 
ELISA 
(1:4000) 
sequence-
based 
reagent 
qRT-PCR 
Oligonucleoti
des 
This study See 
Supplementary 
file 2 
  
commercial 
assay or kit 
Customized 
multiplex 
suspension 
detection 
system  
R&D Systems   
commercial 
assay or kit 
Accutase® 
Cell 
Detachment 
Solution 
 Biolegend 
 Cat. #423201 
 
  
chemical 
compound, 
drug 
Fixable 
Viability 
Dye 
eFluor™ 
506 
ThermoFisher Cat. # 65-0866-14 
 
software, 
algorithm 
FlowJo 
software 
(v10) 
Ashland, OR, 
USA  
https://www
.flowjo.com 
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software, 
algorithm 
RStudio 
software 
(v1.4.1106) 
RStudio, 
Boston, MA, 
USA 
 
https://www
.rstudio.co
m 
software, 
algorithm 
Cytoscape 
software 
(v3.8.1) 
NIGMS, 
Bethesda, 
MD, USA 
 
https://cytos
cape.org 
software, 
algorithm 
GraphPad 
Prism 9 
(v9.1.1 
(223)) 
GraphPad 
Software, San 
Diego, CA, 
USA 
 
graphpad.co
m 
Software, 
algorithm 
ImageJ 
software 
NIH, 
Bethesda, 
MD, USA 
 imagej.nih.
gov 
 510 
Patients 511 
Peripheral blood and plasma samples was collected from 79 patients infected with P. 512 
vivax, as diagnosed by light microscopy, seen at FMT-HVD and 34 healthy donors (controls). 513 
Patients and healthy donors were age and sex-matched, with a frequency of 30% female and 514 
70% male individuals in both groups. All individuals within the study were from a local 515 
vivax malaria epidemic area in the Amazon region of Brazil. All patients included were 516 
outpatients that did not meet World Health Organization (WHO) criteria for severe malaria. 517 
Diagnosis was further confirmed by quantitative PCR (qPCR) for both P. vivax and P. 518 
falciparum, using previously published nucleotide sequences 
70
. Excluding other 519 
coinfections could have been of interest. However, the differential diagnosis for an acute 520 
febrile illness is very broad and it would be impractical to track all other possible 521 
diseases. In addition, the patients included in the present work had mild disease, and 522 
therefore were discharged from hospital after a positive malaria diagnosis.  No further 523 
investigation on other infections was done.  The main coinfection to be considered for an 524 
acute febrile illness with no localizing signs in our context is Dengue Fever. Although 525 
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Dengue coinfection in our cohort is possible, the incidence at the Hospital is only 2.8% 526 
(P. vivax/Dengue coinfection)
71
. Thus, it is unlikely that such a coinfection would have a 527 
major impact on our findings. Exclusion criteria were i) under 18 years of age, ii) 528 
pregnancy, iii) use of antimalarials, iv) chronic disease, v) medication known to interfere 529 
with platelet count/function and vi) smoking.  530 
Anaemia is defined as haemoglobin < 12.5g/dL; haematocrit < 37%; RBCs counts < 531 
4.45x10
6
/L. Thrombocytopenia is defined as a decrease in platelet counts to below 532 
<150,000/𝜇L. Based on platelet levels, patients were grouped into (i) non-thrombocytopenia 533 
(NT: platelet counts >150,000/𝜇L), (ii) mild thrombocytopenia (MT: platelet counts 100,000-534 
150,000/𝜇L), (iii) moderate thrombocytopenia (MDT: platelet counts 50,000-100,000/𝜇L), 535 
and (iv) severe thrombocytopenia (ST: platelet counts <50,000/𝜇L). Lymphopenia was 536 
defined as a lymphocyte count of less than 1,000 cells/𝜇L. Neutropenia was defined as a 537 
neutrophil count of less than 1,500 cells/𝜇L and neutrophilia as a neutrophil count of more 538 
than 7,000 cells/𝜇L 32,72. 539 
 540 
Preparation of poor platelet plasma  541 
After signing the informed consent, 20 mL of venous blood were drawn by venepuncture in a 542 
syringe with 15% acid citrate dextrose as anticoagulant to minimize in vitro platelet 543 
activation. Complete blood counts were done within 15 minutes of blood sampling with a 544 
Sysmex KX21N counter. Whole blood was centrifuged at 180 g for 18 minutes at room 545 
temperature, without brake for gradient formation, to obtain the platelet rich plasma (PRP). 546 
PRP was centrifuged at 100 g for 10 minutes for removal of residual leukocytes, and 547 
subsequently centrifuged at 800 g for 20 minutes to obtain the platelet pellet. Prostaglandin 548 
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E1 at 300 nM was used to minimize platelet aggregation. The supernatant was centrifuged at 549 
1000 g for 10 minutes to obtain platelet poor plasma (PPP). 550 
 551 
Multiplex bead array assay 552 
The biomarkers were analysed in thawed plasma with a customized multiplex suspension 553 
detection system (R&D Systems) for quantification of the following biomarkers:  554 
a) pro-inflammatory and myelopoiesis-inducing cytokines: TNF-, IL-1, IL-1, IL-6, 555 
IL-8, G-CSF 556 
b) endothelial cell (EC) activation and coagulation markers: ICAM-1, VCAM-1, E-557 
selectin, P-selectin, Angiopoietin-1 (Ang-1), Angiopoietin-2 (Ang-2), von Willebrand 558 
Factor (vWF-A2), CD40L, PAI-1, ADAMTS13 559 
c) glycocalyx breakdown and EC damage marker: Syndecan-1 560 
d) platelet activation markers: CXCL4 and CXCL7 561 
e) megakaryocyte differentiation-inducing cytokines: thrombopoietin (TPO) and IL-11; 562 
and other proteins such as IL-10, L-selectin and SCF.  563 
A representative set of 31 P. vivax patients were selected for the multiplex assay (Figure 564 
1-figure supplement 1). These patients were selected to encompass the wide range of 565 
peripheral parasitemia present in the cohort (260 to 25,150 infected RBCs/μL) and to 566 
match age, gender and other haematological parameters to those that were not selected.  567 
Nine healthy donors matched for age and sex were also selected.  568 
 569 
Plasmodium vivax lactate dehydrogenase (PvLDH) ELISA 570 
To measure PvLDH in patient plasma samples, ELISA was performed using a matching pair 571 
of capture and detection antibodies (Vista Diagnostics International LLC, Greenbank, WA, 572 
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USA). Briefly, 96-well microtiter plate was coated with monoclonal anti-pLDH Vivax-573 
specific (clone 3H8 - Vista Diagnostics International LLC, WA, USA; RRID: AB_2892826) 574 
at a concentration of 1g/mL in PBS (pH 7.4) and incubated overnight at 4
o
C. The plate was 575 
washed and incubated with blocking buffer (reagent diluent) at room temperature for 1h. 576 
After washing, samples were added and incubated for 2h. Next, plates were washed and 577 
biotinylated anti-PvLDH detection antibody (clone 6c9 - Vista Diagnostics International 578 
LLC, WA, USA; RRID: AB_2892827), diluted 1:4000 in blocking buffer, was incubated for 579 
2h at room temperature, followed by streptavidin-HRP incubation for 20 minutes at room 580 
temperature. Plates were washed and incubated for 20 min with substrate solution. Optical 581 
density was determined at 450 nm. Cut-off of positivity was defined by correcting 582 
absorbance values generated in the plasma samples from healthy donors (controls) by blank 583 
values (plate controls), with both values being in the same range. Absorbance values higher 584 
than controls were considered positive. In parallel, we used schizont extracts to perform 585 
standard curves and lower absorbance values were in the range of O.D = 0.03-0.04. All 586 
positive patient samples gave O.D. values equal or higher than 0.05. 587 
 588 
Principal component analysis and K-means hierarchical clustering  589 
Haematological parameters (haemoglobin levels, haematocrit, differential blood cell counts), 590 
parasite parameters (peripheral parasitaemia by blood smear, parasite load by qPCR and 591 
parasite biomass PvLDH ELISA) and Luminex data (24 biomarkers) from the selected 9 592 
healthy donors and 31 P. vivax patients were normalized to avoid variable-specific bias and 593 
z-score values were determined. Since the host response is complex and multidimensional 594 
(one dimension per Luminex biomarker), we applied dimension reduction and clustering for 595 
ease of downstream analysis. For this, all variables were used as input for principal 596 
component analysis (PCA) to reduce the dimensionality of data using the PCA function in the 597 
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FactoMineR package in R. For visualization of PCA results ggplot2, factoextra and corrplot 598 
packages were used. For each principal component (PC), we determined which variables are 599 
better represented and the contribution (correlation or loading score) of each variable for each 600 
(PC). Investigation of eigenvalues and the percentage of explained variances retained by the 601 
PCs demonstrated that the first 10 PCs accounted for the variance of the data (Figure 2-602 
figure supplement 1). However, variables were well represented by the first 2 PCs (Dim 1 603 
and Dim 2), which were therefore retained for further analysis. In parallel, we performed K-604 
means Clustering (k) followed by bootstrapping, which produced the most stable clusters 605 
with k = 2 (Cluster 1 = 21 individuals; Cluster 2 = 18 individuals), which seemed to be the 606 
most consistent with the data (Figure 2A, Figure 2-figure supplement 1, Figure 2-figure 607 
supplement 2, Figure 2-figure supplement 2-source data1). Figure 2-figure supplement 608 
2-source data1 contains the numerical data representing cluster stability via bootstrapping. 609 
The metrics of interest is jaccard_index which measures the cluster similarity across 610 
bootstrap samples. Similar to the above, k=2 gives stable clusters for all configurations 611 
(jaccard_index 0.9 and 0.86). Using Monte Carlo Reference-based Consensus Clustering 612 
(M3C) analysis (M3C function in the M3C package in R) indicated that k=2 is the optimal 613 
number of clusters when using K-means clustering (Figure 2-figure supplement 2C, D), but 614 
when determining spectral clusters, different from elliptical k-means clusters, k=3 gives the 615 
best number of clusters (Figure 2-figure supplement 2E-G).  616 
 617 
Correlation plots and heatmap visualization 618 
Heatmaps were created to visualize variable values using R function Complex Heatmap. 619 
They represent z-scores using row scaling obtained by centring represented variables with the 620 
scale function, followed by column clustering using average cluster method and Euclidean 621 
distance metric in R. The same software was used to determine pairwise Pearson’s 622 
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correlation coefficients between variables by running the function cor in the ggcorrplot 623 
package and visualized as a correlogram using R function corrplot in the Hmisc package 624 
displaying positive correlations in red and negative correlations in blue using p ≤ 0.01 as a 625 
cut-off. 626 
 627 
Recursive partitioning decision-tree classification and machine learning models 628 
We used recursive partitioning decision-tree classification models to evaluate dominant 629 
signatures (attributes) predicting a specific outcome. For decision-tree construction we 630 
applied the C4.5 algorithm, using the RWeka, caret (Classification and Regression Training) 631 
and e1071 packages or the rpart package in R. First, the library caret is used to create a 10-632 
fold training set to train the model. Then, the algorithm implements decision trees (using the 633 
J48 method, which is an open-source Java implementation of the C4.5 algorithm) starting 634 
with all instances in the same group, then repeatedly divides the data based on attributes until 635 
each item is classified. The attribute on which to divide is selected by information gain, a 636 
statistical technique for determining which attribute split will most cleanly divide the data. To 637 
avoid overfitting, sometimes the tree is pruned back. In parallel, the algorithm performs k-638 
fold cross validation to measure the performance of a given predictive model and indicates 639 
which one has the higher accuracy. Here, we used k=10 to yield test error rate estimates that 640 
suffer neither from excessively high bias nor from very high variance 
73
. In parallel, features 641 
with mean decrease accuracy larger than 6 were used for random forest. In the random forest 642 
analysis, a thousand trees were built using R package randomForest (version 4.6.14). The 643 
normalized additive predicting probability was computed as the final predicting probability. 644 
Those selected important features were used for the random forest analysis on the test cohort 645 
for model validation.  646 
 647 
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Stimulation of HUVEC with patients’ plasma pools  648 
After standardization procedures, primary human umbilical vein endothelial cells (HUVEC) 649 
were stimulated or not (mock control) in culture media for 6h – to evaluate mRNA 650 
expression – or for 18h – to evaluate protein expression - with complete EGM-2 medium 651 
(Lonza) containing 30% (v/v) plasma pools generated from the three subgroups - Healthy 652 
control, Vivax
low
 and Vivax
high
 - and 3U/L heparin.  653 
 654 
Real-Time Quantitative RT- PCR 655 
After 6h stimulation, total RNA was isolated from the cell lysate using the miRVana miRNA 656 
Extraction kit (Ambion) according to the instructions of the manufacturer. cDNA was 657 
synthesized with TaqMan Reverse Transcriptase (Applied Biosystems, Foster City, CA) and 658 
mRNA expression of genes were determined by qRT-PCR. Real-time qRT-PCR was 659 
performed on an ABI-Prism 7000 PCR cycler (Applied Biosystems) or on the CFX96 Real-660 
Time PCR Detection System (Bio-Rad). Cycling parameters were 95°C for 1min and then 35 661 
cycles of 95°C (15s) and 60°C (1min), followed by a melting curve analysis. The median 662 
cycle threshold (Ct) value and 2
-Ct
 method were used for relative quantification analysis, 663 
and all Ct values were normalized to the GAPDH mRNA expression level. Results expressed 664 
as means and SEM of biologic replicates are shown. The mock sample (HUVECs incubated 665 
with culture media only) was used as reference. The oligonucleotides used are described in 666 
the Supplementary File 2. 667 
 668 
Endothelial cell Flow Cytometry (FC) and Immunofluorescence Analysis (IFA) 669 
For immunofluorescence analysis, cells were grown in 8-well chambered coverslips 670 
(IBIDI) until confluence. After 18h stimulation with plasma pools, cells were washed with 671 
PBS and fixed/permeabilized with ice cold 100% methanol for 5 minutes at -20°C. In brief, 672 
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cells were incubated with 10% goat serum (ThermoFisher) to avoid secondary antibody 673 
nonspecific binding for 1h at room temperature and then incubated with specific primary 674 
antibodies to human ICAM-1 (mouse monoclonal clone MEM-111; Abcam; cat. number 675 
ab2213; RRID: AB_302892) (used at a dilution of 1:100 in 10% goat serum); VCAM-1 676 
(mouse monoclonal clone 1.4C3; Abcam; cat. number ab212937; RRID: AB_2892824) (used 677 
at a dilution of 1:500 in 10% goat serum) and mouse IgG1 isotype control (Dako; cat. 678 
Number X0931; RRID: AB_2892825) (used at a dilution of 1:10 in 10% goat serum) 679 
overnight at 4°C. After washing, wells were overlaid for 1h with AF488-conjugated 680 
secondary antibody (used at a dilution of 1:500 in 10% goat serum) and Hoechst (diluted at 681 
1:2000) at room temperature. For controls, primary antibodies were omitted from the staining 682 
procedure and were negative for any reactivity. The chambers were placed at 4°C until use 683 
for immunofluorescence assay (IFA). Percentage of positive cells and expression profiles for 684 
ICAM-1and VCAM-1 were then determined using ImageJ  software (NIH, Bethesda, MD, 685 
USA). 686 
In flow cytometry, after 18h stimulation with 30% plasma pools, cells were washed 687 
2x with DPBS and treated with Accutase® Cell Detachment Solution (Biolegend) at room 688 
temperature for up to 3 minutes, or until the cells are detached. Cell count and viability with 689 
trypan blue dye were determined and cells were resuspended in ice cold DPBS without 690 
calcium/magnesium, 0.5mM EDTA, 10% foetal bovine serum (FBS) (GIBCO).  Cells were 691 
incubated with FcBlock (BD Biosciences, San Jose, CA, USA), followed by incubation with 692 
unconjugated anti-VCAM (mouse monoclonal clone 1.4C3; Abcam; cat. number ab212937) 693 
or AF488-conjugated anti-ICAM-1 (mouse monoclonal clone HCD54; Biolegend; cat. 694 
number 322714; RRID:AB_535986) or unconjugated mouse IgG1 isotype control (Dako; cat. 695 
Number X0931) for 1h at 4°C. Cells were then washed and incubated for 1h at 4°C with 696 
secondary antibody AF488-conjugated anti-mouse IgG (ThermoFisher). Finally, cells were 697 
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incubated with Fixable Viability Dye eFluor™ 506 (ThermoFisher) in DPBS without 698 
calcium/magnesium, 0.5mM EDTA for 30min at 4°C. Cells were washed and resuspended in 699 
buffer and acquired using a BD FACSCelesta cytometer (100,000 events/sample). Percentage 700 
of positive cells and expression profiles for ICAM-1and VCAM-1 were then determined by 701 
the mean fluorescence intensity using FlowJo software (v10; Ashland, OR, USA). 702 
 703 
Ex vivo Evaluation of Endothelial cell Monolayer Function 704 
Endothelial cell monolayer function was measured using ECIS, an electric cell-substrate 705 
impedance sensing system (ECIS Zθ, Applied BioPhysics, Troy, NY), as previously 706 
described 
74
. The system then applies weak alternating currents through the electrode array 707 
and continuously measures the ability of the cell monolayer to impede the movement of 708 
electrons between adjacent endothelial cells (resistance). Briefly, cells were seeded at 2.5 × 709 
10
5
 cells/well on fibronectin-coated (10 µg/ml) eight-well arrays (8WE10, Applied 710 
BioPhysics, Troy, NY) containing interdigitated gold electrodes. Endothelial cells were 711 
seeded 48 h before experiments and the resistance started to be recorded after 48 h. Only 712 
wells with resistance > 1,500 ohms and stable impedance/resistance readings were used. 713 
Before stimulation, resistance was continuously monitored for 2 h, to confirm monolayer 714 
stability represented by a plateau in the resistance curve. Stimuli (20% v/v pooled plasma in 715 
complete medium) was then added to wells under continuous impedance/resistance 716 
monitoring for 12h. A baseline resistance value was recorded immediately prior to the 717 
addition of each stimuli and results are expressed as a ratio from baseline resistance 718 
(normalized resistance).  719 
Network analysis   720 
The values of each circulating factor measured in the plasma samples, as well as 721 
haematological parameters and parasite biomass in healthy donors and P. vivax malaria 722 
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patients were input in the RStudio software (Version 1.4.1106, 2021) to determine pair-wise 723 
Pearson’s correlation coefficients to generate correlation networks and the p-value to test for 724 
non-correlation was evaluated using p ≤ 0.05 as a cut-off. In order to analyse the structure of 725 
the networks, edges list was generated in R using the functions melt (reshape2 package), 726 
graph_from_edgelist (igraph package). Graphs were customized in the Cytoscape software (v 727 
3.8.1) using the force-directed layout, which simulates a system of forces, determined by the 728 
correlation strength. In the in the equilibrium state edges tend to have uniform length, and 729 
nodes that are not connected by an edge tend to be drawn further apart. Network topology 730 
and module analysis were performed using the NetworkAnalyzer, jActiveModules and 731 
MCODE plugins in Cytoscape 
75,76
.  Supplementary File1 shows the results for all 732 
parameters quantified in the comparative network topology analysis between the 733 
graphs for healthy donors and P. vivax patients. 734 
 735 
Statistical Analysis  736 
Fisher’s exact test was used for categorical data. Data normality was checked by the 737 
Shapiro-Wilk test. Student’s t-test was used to compare means between groups with normally 738 
distributed data, and data sets with non-normal distributions were compared using the Mann–739 
Whitney test. All tests were performed two-sided, using a nominal significance threshold of p 740 
< 0.05 unless otherwise specified. When appropriate to adjust for multiple hypothesis testing, 741 
Tukey’s or Bonferroni corrected multiple comparisons test significance at the p-value < 0.05 742 
threshold was performed unless otherwise specified. Data are presented as scatter plots with 743 
median and 25%-75% interquartile range, box plots showing minimum to maximum range or 744 
means and SEM, unless otherwise stated. Analyses were performed and the graphs generated 745 
in GraphPad Prism 9 (Version 9.1.1 (223), 2021) and RStudio software (Version 1.4.1106; 746 
2021). To ensure that differences observed between P. vivax - infected patients and controls, 747 
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as well as between the clusters, were due to disease status and not confounded by age or sex, 748 
the clinical parameters were fitted as response variables in a linear model with sex and/or age 749 
fitted as explanatory variables. Age and sex were included in the model if their coefficients 750 
were estimated as different from zero with p-value < 0.05. The residuals from the linear 751 
model were then used as age and/or sex corrected parameters in subsequent analyses. 752 
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Figure legends 1028 
Figure 1: Clinical data of P. vivax patients (Pv) and healthy donors (HDs). (A) Red 1029 
blood cell parameters. Shown are red blood cell counts, hemoglobin levels and hematocrit. 1030 
(B) Other blood cell parameters. Shown are numbers of leukocytes, neutrophils, and 1031 
monocytes, basophils and eosinophils (MXD). (C) Number of lymphocytes, platelets and 1032 
mean platelet volume (MPV). Parameters are depicted as box plots showing each individual 1033 
value and the median with maximum and minimum values. Dashed lines in black mark the 1034 
minimum threshold for normal reference values, while lines in red mark threshold for severe 1035 
lymphopenia and thrombocytopenia, respectively. Two-tailed student’s t-test was used to 1036 
compare variables with normally distributed data, and Mann-Whitney test was used to 1037 
compare variables with non-normal distributions; p-value is indicated above the graph when 1038 
p < 0.05. HDs = healthy donors (controls, n= 34); Pv = P. vivax-infected patients (n = 79). 1039 
 1040 
Figure 1-figure supplement 1: Demographic and clinical features of all P. vivax-infected 1041 
patients compared with selected 31 patients for multiplex-bead based assay and 1042 
downstream analysis. (A) Gender, age and hematological parameters compared between all 1043 
79 P. vivax-infected patients (All) and those 31 selected for downstream molecular analysis. 1044 
(B) Comparison of gender, age and hematological parameters between 31 selected (S) P. 1045 
vivax-infected patients with the remaining 48 non-selected (NS) patients. Parameters are 1046 
depicted as box plots showing each individual value and the median with maximum and 1047 
minimum values. 1048 
 1049 
Figure 2: Characterization of heterogeneity in symptomatic P. vivax patients defines 1050 
clusters of individuals. (A, B) Clustering of patients and healthy controls. After z-score 1051 
normalization, Principal Component Analysis (PCA) was performed for data dimensionality 1052 
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reduction. K-means Clustering using k=2 followed by bootstrapping (1,000 times) in a PCA 1053 
plot was performed and produced the most stable clusters regardless of the starting point (ln 1054 
1,000/1,000): Cluster 1 = 23 individuals comprising of 9 healthy donors and 14 P. vivax 1055 
patients and Cluster 2 comprising 17 P. vivax patients. The jaccard_index measures cluster 1056 
similarity across bootstrap samples (jaccard_index ranges from 0 to 1, an index < 0.6 hints at 1057 
a weak, unreliable cluster while > 0.85 means generally reliable). As indicated in the PCA 1058 
plot, k=2 gives stable clusters for all configurations (jaccard_index 0.9 and 0.86) and withinss 1059 
(wss) = 1,122. Open ovals represent 95% confidence interval ellipses around group mean 1060 
points. Principal Component Analysis (PCA) was performed for data dimensionality 1061 
reduction, in parallel with K-means Clustering (k) followed by bootstrapping (1,000 times). 1062 
Open ovals represent 95% confidence interval ellipses around group mean points. (B) The 1063 
resulting clusters represent healthy controls (1a) and patients (1b, 2). (C) Contribution of 1064 
variables to clustering. In the circular plot the correlation between each input variable and 1065 
principal components is used as coordinates (loading score). Plots shows how covariables 1066 
determine patient distribution in the PCA plot.  1067 
 1068 
Figure 2-figure supplement 1: Principal components analysis metrics. (A, B) Analysis of 1069 
eigenvalues (measure of the amount of variation retained by each principal component) and 1070 
the percentage of explained variances retained by the PCs demonstrated that the first 10 PCs 1071 
accounted for the variance of the data. (C) However, most of the variables were highly 1072 
represented in the first 2 PCs (Dim 1 and Dim 2), which were therefore retained for further 1073 
analysis.  1074 
 1075 
Figure 2-figure supplement 2: Methods determining the number of clusters best 1076 
representing the data. (A, B) PCA plots indicating different K-means cluster configurations, 1077 
using k= 3 and k=4 clusters, respectively after performing bootstrapping. With k=3 different 1078 
starting points give different clusters. The two most common clusters (top row) are very 1079 
similar and they are obtained in 241 and 179 starts out of 1,000, respectively. However, the 1080 
clustering that best represents the data when k = 3 is the third one found in 168/1000 starting 1081 
points as its withinss (wss) metric is lower (highlighted in red). Indeed, this configuration is 1082 
more equivalent to those clustering configurations when k=2. (B) Clusters seem more stable 1083 
when k=4. Accordingly, the best clustering appears to be the ones represented in the bottom 1084 
row, which contains two main groups and two small groups with just 2 patients. (C, D) The 1085 
second method used was the Monte Carlo Reference-based Consensus Clustering (M3C), 1086 
which also indicated that k=2 is the optimal number of clusters, as indicated in (C) the flat 1087 
line in the CDF plot and (D) in the highest Relative Cluster Stability Index (RCSI) plot. (E, 1088 
F, G). Using spectral clusters, instead of elliptical K-means clusters, M3C analysis indicates 1089 
that k=3 gives the optimal number of clusters, as indicated in the (E) CDF plot, (F) RCSI plot 1090 
and (G) the NXN consensus matrix, where each element represents the fraction of times two 1091 
samples clustered together.  1092 
 1093 
Figure 2-source data 1: Correlation (loading score) of variables to principal 1094 
components.  1095 
 1096 
Figure 2-figure supplement 2-source data 1: Measurements of K-means cluster stability, 1097 
using k=2, k=3 and k=4 clusters, via bootstrapping. 1098 
 1099 
Figure 3: Unsupervised clustering analysis reveals two P. vivax patient subgroups that 1100 
differ in parasite biomass. (A) Parasite parameters vs patient clusters. Comparison of the 1101 
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two patient clusters (Cluster 1b and Cluster 2) across parasite parameters reveals significant 1102 
differences with total parasite biomass (PvLDH) but not peripheral parasitaemia or parasite 1103 
load (copies of 18s rRNA/L of blood). (B) Parasite biomass vs parasitemia across 1104 
clusters. Heatmap represents z-scores of PvLDH with peripheral parasitemia or parasite load, 1105 
respectively. Black boxes highlight patients with relatively lower peripheral parasitemia 1106 
compared to PvLDH levels, indicating the underestimation of total parasite biomass based on 1107 
peripheral parasitemia values. (C) Correlation between parasite biomass and parasitemia. 1108 
Scatter plot showing lack of correlation between PvLDH and peripheral parasitemia or 1109 
parasite load, respectively. Regression line in red, with 95% confidence interval shown in 1110 
shaded gray. (D, E) Predicting parasite clusters. (D) Top parameters prioritized by random 1111 
forest analysis ranked by the mean decrease in accuracy. (E) Best-fit decision trees and 1112 
random forest machine learning models corroborate PvLDH value as the most important 1113 
parasite signature in segregating patients into clusters 1b and 2. Cut-off values of the attribute 1114 
that best divided groups were placed in the root of the tree according to the parameter value. 1115 
The total of classified registers for each class and the percentage of observations used at that 1116 
node are given in each terminal node.  1117 
 1118 
Figure 4: More severe haematological alterations in Vivax
high
 compared to Vivax
low 
1119 
patients. (A) Patient data and hematological parameters. Comparison of patient age, 1120 
average days of symptoms when samples were collected, haemoglobin levels, haematocrit or 1121 
RBC counts across patient clusters (Control: n=9; Vivax
low : 
n=14; Vivax
high
: n=17). Data are 1122 
depicted as plots showing individual values and the median (black lines) and the interquartile 1123 
range. (B) Blood cell counts. Comparison of differential haematological counts across 1124 
clusters. Shown are. numbers of platelets, lymphocytes, neutrophils and monocytes, basophils 1125 
and eosinophils (MXD), neutrophil to total leukocyte ratio and neutrophil to lymphocyte ratio 1126 
(NLCR). Top dashed lines mark the minimal threshold for normal reference values, while 1127 
bottom dashed lines mark the threshold for severe lymphopenia and thrombocytopenia, 1128 
respectively. Parameters are depicted as plots showing individual values and the median 1129 
(black lines) and the interquartile range. One-way analyses of variance with Bonferroni-1130 
corrected multiple comparisons test were performed. p-value is indicated above the graph 1131 
when reached significance of p < 0.05. (C) Cytokine response and neutrophil activation 1132 
across clusters. Heatmap represents z-scores obtained by centering values of Luminex data. 1133 
Shown are thrombopoiesis-inducing cytokines, myelopoiesis-inducing cytokines and 1134 
neutrophil activation markers.  Biomarker concentrations were normalized (scale function in 1135 
R) and the average scaled value is showed in blue and yellow scales. Blue shading represents 1136 
the highest average scaled value; yellow shading, the lowest average scaled value. Each 1137 
column (i.e., individual) in the heatmap is matched with color-coded cluster assignment: 1138 
Cluster Control – green bar; Cluster Vivax
low
 – blue bar and Cluster Vivax
high
 – red bar.  1139 
 1140 
Figure 4-figure supplement 1: Increase of thrombopoiesis- and myelopoiesis inducing 1141 
cytokines in the plasma of Vivax
high 
patients. (A) Levels of myelopoiesis-inducing 1142 
cytokines, (B) thrombopoiesis-inducing cytokines thrombopoietin (TPO) and IL-11 and (C) 1143 
neutrophil activation markers in the acute-phase patients’ plasma samples of our cross-1144 
sectional cohort in Manaus, Brazil, were determined by multiplex-bead based assay 1145 
(Luminex): Control (healthy donors, n = 9), Vivax
low
 patients (n=14) and Vivax
high
 patients 1146 
(n=17). Biomarkers’ concentration is depicted as scatter plots showing individual data points 1147 
and the median (black lines) and the interquartile range. One-way analyses of variance with 1148 
Bonferroni-corrected multiple comparisons test were performed. p-value is indicated above 1149 
the graph when reached p < 0.05. 1150 
 47 
 1151 
Figure 5: Elevated circulating markers of EC activation and damage in Vivax
high
 1152 
compared to Vivax
low 
patients. (A) Endothelial changes across clusters: Luminex. 1153 
Heatmap represents z-scores obtained by centering values of Luminex data. Shown are 1154 
markers of endothelial cell (EC) activation, procoagulation and glycocalyx damage. Each 1155 
column (each individual) in the heatmap is matched with color-coded cluster assignment: 1156 
Cluster Control – green bar; Cluster Vivax
low
 – blue bar and Cluster Vivax
high
 – red bar. (B) 1157 
Endothelial changes across clusters: qRT-PCR. Transcriptional response of HUVECs 1158 
incubated for 6h with 30% v/v pooled plasma from different clusters. Heatmap reflects 1159 
relative mRNA expression intensity (average scaled value) after results were normalized to 1160 
GAPDH housekeeping gene expression and untreated condition (mock). Data shown 1161 
represent the mean of three independent experiments. For each experiment, 2 technical 1162 
replicates were performed for each condition. (C) Endothelial changes across clusters: 1163 
impedance changes. Endothelial monolayer integrity was measured during 20% v/v of 1164 
pooled plasma incubation. Each line represents the mean ± SD of normalized resistance of 1165 
HUVECs measured by ECIS at 4,000 Hz. Data shown are representative of three independent 1166 
experiments. For each experiment, 2 technical replicates were performed for each condition.  1167 
(D) Endothelial changes across clusters: imaging and flow cytometry. HUVECs were 1168 
incubated for 18h with 30% v/v of pooled plasma of individuals in the different clusters or 1169 
left untreated (mock). Percentage of cells expressing EC activation markers (adhesion 1170 
molecules) ICAM and VCAM as well as quantification of protein expression was determined 1171 
by flow cytometry and immunofluorescence analysis (scale bar = 33M). Isotype antibodies 1172 
were used as control to define positive populations. Significance was calculated for 1173 
comparisons between conditions at the corresponding time point using. One-way analyses of 1174 
variance statistical test with Tukey’s corrected multiple comparisons test. p-value is indicated 1175 
above the graph when p < 0.05. Data shown are representative mean ± SEM of three 1176 
independent experiments. 1177 
 1178 
Figure 5-figure supplement 1: Increase of markers of endothelial cell activation, 1179 
damage (glycocalyx breakdown) and procoagulation in the plasma of Vivax
high 
patients. 1180 
(A) Levels of EC activation markers, (B) procoagulant phenotype and (C) EC damage 1181 
(glycocalyx breakdown) in the acute-phase patients’ plasma samples of our cross-sectional 1182 
cohort in Manaus, Brazil, were determined by multiplex-bead based assay (Luminex): 1183 
Control (healthy donors, n = 9), Vivax
low
 patients (n=14) and Vivax
high
 patients (n=17), as 1184 
indicated in the legend (top right corner). Biomarkers’ concentration is depicted as scatter 1185 
plots showing individual data points and the median (black lines) and the interquartile range. 1186 
One-way analyses of variance with Bonferroni-corrected multiple comparisons test were 1187 
performed. p-value is indicated above the graph when reached significance of p < 0.05. (D) 1188 
Quantitative mRNA expression was determined by qRT-PCR in RNA extracted from 1189 
HUVECs incubated for 6h with 30% v/v pooled-plasma of individuals in the different 1190 
clusters, as indicated in the legend (top right corner). Graphs depict relative expression after 1191 
results were normalized to GAPDH housekeeping gene expression. The data shown are mean 1192 
 SEM representative of three independent experiments. Significance was calculated for 1193 
comparisons between conditions at the corresponding time point using One-way analyses of 1194 
variance with Tukey’s corrected multiple comparisons test. p-value is indicated above the 1195 
graph when reached significance of p < 0.05. (E) Schematics of HUVECs gating strategy 1196 
used for flow cytometry analysis. Endothelial cells gate (ECs) was defined based on the cells’ 1197 
forward scatter (FSC) and side scatter (SSC). Further, gated single cells on FSC-A vs FSC-H 1198 
scatter plot and selected live cells based on Fixable Viability Dye eFluor™ 506 staining.  1199 
 48 
 1200 
Figure 5-figure supplement 2: Haemolysis potentiates Vivax
high
-induced EC activation. 1201 
In order to mimic the environment associated with commencement of anti-malarial treatment, 1202 
such as content released from haemolysis of RBCs and dead parasites biproducts, HUVECS 1203 
were stimulated with either P. vivax-infected (schizont enriched) or uninfected RBCs lysates 1204 
in 30% v/v pooled-plasma of individuals in the different clusters. For the parasite lysates, 1205 
batch pellets of P. vivax iRBCs enriched of schizonts, isolated from blood of P. vivax-1206 
infected patients using Percoll gradient centrifugation, and healthy donor RBCs were stored 1207 
at −80 °C without any cryopreservative agent. Pellets were twice freeze–thawed for use as 1208 
whole lysates. Total RNA was extracted 6h after treatment and relative mRNA expression 1209 
determined by real-time quantitative PCR. Graphs depict relative expression after results 1210 
were normalized to GAPDH housekeeping gene expression. The data shown are mean  1211 
SEM representative of three independent experiments. Significance was calculated for 1212 
comparisons between conditions at the corresponding time point using One-way analyses of 1213 
variance with Tukey’s corrected multiple comparisons test. p-value is indicated above the 1214 
graph when reached significance of p < 0.05. Haemolysis of either P-vivax-infected or 1215 
uninfected RBCs potentiates the effect of Vivax
high
 pooled plasma in inducing transcriptional 1216 
upregulation of EC activation markers. Different from the stimulation only with plasma, in 1217 
the presence of haemolysis, we also observed upregulation of Ang-2 and VEGF, and 1218 
downregulation of NOS3, markers associated with perturbation of the vascular integrity and 1219 
function. 1220 
 1221 
 1222 
Figure 6: Network analysis and clustering of parasite and host signatures indicate 1223 
parasite-induced changes in deep tissues.  (A) Network analysis. Networks of the 1224 
Pearson’s correlations (absolute coefficient above 0.5 and p-value < 0.05) between parasite 1225 
biomass (PvLDH) and host signatures in healthy donors (left graph) and in P. vivax-infected 1226 
patients (right graph), using a force-directed layout. The symbols of the nodes represent 1227 
biological functions: triangle represents markers of platelet activation and thrombopoiesis-1228 
inducing cytokines; V shape represents haematological parameters (neutrophil, lymphocyte 1229 
and platelet counts); circles represent endothelial cell activation markers; squares represent 1230 
myelopoiesis-inducing cytokines and neutrophil activation markers. The colors in the nodes 1231 
represent the fold change in relation to control levels. Because healthy donors do not have 1232 
parasitemia, PvLDH node is represented in black. Each connecting line (edge) represents a 1233 
significant interaction detected by the network analysis using R. Correlation strength is 1234 
represented by edge color transparency and width. Positive correlations are represented by 1235 
red edges and negatives correlations are represented by blue edges. (B,C) Correlation 1236 
matrix and heatmap. (B) Representative image of Pearson’s correlation matrix calculated 1237 
for all P. vivax patients. Only correlations with p-value <0.01 are shown and hierarchical 1238 
clustering was applied. Red circles highlight positive correlations in the functional modules 1239 
depicted in (A), and blue circles highlight negative correlations in the functional modules 1240 
also depicted in (A). (C) Heatmap showing p-values of the correlations between different 1241 
parasite parameters, parasite biomass (PvLDH) and peripheral parasitemia and host 1242 
signatures (hematological and Luminex parameters). (D) Decision tree model. Best-fit 1243 
classification tree model generated with the C4.5 algorithm showing Syndecan-1, IL-6 and 1244 
platelet counts are the dominant variables capable to predict total parasite biomass in P. vivax 1245 
patients. Cut-off values of the attribute that best divided groups were placed in the root of the 1246 
tree according to the parameter value (pg/mL for soluble markers or number of cells x 1247 
1,000/L of blood for platelet counts). The total of classified registers for each class are 1248 
 49 
given in parentheses for each terminal node with the k-fold cross-validation (k-fold CV) 1249 
accuracy indicated.  1250 
 1251 
Figure 6-figure supplement 1: Representative images of Pearson’s correlation matrix 1252 
calculated separately for each P. vivax patient cluster. (A) Vivax
low
 patients (n=14). (B) 1253 
Vivax
high
 patients (n=17). A reduced complexity model was established by focusing on 1254 
informative interactions between P. vivax and host signatures determined by Pearson’s 1255 
correlation coefficients. Only correlations with associated p-value <0.01 are shown and 1256 
hierarchical clustering was applied.  1257 
 1258 
Figure 6-figure supplement 2: Validation of patients’ clusters and correlations when 1259 
segregating patients based on thrombocytopenia severity. Box plots showing (A) parasite 1260 
parameters, clinical parameters and biomarkers measured on plasma samples were generated 1261 
segregating patients based on levels of thrombocytopenia severity (normal, mild, moderate 1262 
and severe) color-coded. (B) Recursive partitioning classification tree model generated with 1263 
the rpart function in R showing the high value of VCAM-1, PvLDH and Syndecan-1 to 1264 
predict thrombocytopenia severity in P. vivax patients. Cut-off values of the attribute that best 1265 
divided groups were placed in the root of the tree according to the parameter value (pg/mL 1266 
for soluble markers or O.D. for PvLDH).  1267 
 1268 
Figure 6-figure supplement 3: Validation of patients’ clusters and correlations when 1269 
segregating patients based on lymphopenia severity. Box plots showing parasite 1270 
parameters, clinical parameters and biomarkers measured on plasma samples were generated 1271 
segregating patients based on levels of lymphopenia severity (normal, moderate and severe) 1272 
color-coded. 1273 
 1274 
Supplementary Files 1275 
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Supplementary File 1: Topological analysis of the network graphs of healthy donors 1278 
and P. vivax patients. 1279 
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Supplementary File 2: Oligonucleotides sequences used in the qRT-PCRs 1281 
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 1319 
Table 1: Demographic, parasite and multiplexed microbead-based immunoassay 1320 
(Luminex) data obtained from the plasma of a representative subset of 31 P. vivax 1321 
patients and 9 healthy donors (controls).  1322 
 1323 
Parameters Healthy donors (n=36) Symptomatic Pv patients (n=79) P-value 
(Pv vs 
control) 
 Median [IQ 25-75] Median [IQ 25-75]   
Age 32 [23-49] 36 [28-45] 0.06 
Parasitemia (10
3
/mL) - 4.29 [1.86-6.62]  
Parasitemia (%) - 0.76 [0.57-1.25]  
Parasite load (copies 
18s RNA/mL) 
- 26,642 [9,253-522,297]  
PvLDH (O.D.) - 0.18 [0.005-0.34]  
Plasma biomarkers Healthy donors (n=9) Symptomatic Pv patients (n=31) P-value 
(Pv vs 
control) 
TNF-α (pg/mL) 17.2 [11.0-22.3] 38.4 [30.0-69.6] <0.0001 
IL-1α (pg/mL) 11.9 [10.0-19.5] 25.4 [19.8-33.5] 0.0004 
IL-1β (pg/mL) 12.0 [8.0-12.8] 21.4 [14.5-27.6] <0.0001 
 51 
IL-6 (pg/mL) 3.0 [2.5-3.7] 33.4 [7.6-133.1] <0.0001 
IL-8 (pg/mL) 2.2 [0.6-2.4] 6.4 [2.7 – 19.9] 0.0005 
IL-10 (pg/mL) --* 314 [169-562] -- 
G-CSF (pg/mL) 9.485 [9.485-9.485] 101.5 [33.49-239.6] <0.0001 
L-Selectin (ng/mL) 326 [287-391] 481 [386-579] 0.0019 
ICAM-1 (ng/mL) 323 [260-464] 634 [456-849] 0.0026 
VCAM-1 (ng/mL) 819 [623-959] 2875 [1753-5108] <0.0001 
E-Selectin (ng/mL) 26.4 [22.5-33.7] 56.7 [41.5-74.1] 0.0001 
P-selectin (ng/mL) 17.0 [15.4-20.6] 22.2 [17.6-25.7] 0.0621 
Angiopoietin-1 (ng/mL) 0.4 [0.3-0.6] 0.5 [0.2-0.9] 0.8874 
Angiopoietin-2 (ng/mL) 1.8 [1.5-2.1] 4.3 [2.7-5.3] 0.0003 
Ang-2:Ang-1 ratio 4.2 [2.7-5.6] 12.14 [2.7-40.2] 0.03 
VWF-A2 (pg/mL) 126 [120-150] 218 [199-277] <0.0001 
ADAMTS13 (ng/mL) 1110 [483-1740] 776 [572-1328] 0.5485 
PAI-1 (pg/mL) 78.9 [62.4-96.4] 112 [69.3-242] 0.1541 
CD40L (ng/mL) 0.5 [0.4-0.7] 1.0 [0.7-1.3] 0.0001 
Syndecan-1 (ng/mL) 1.8 [1.6-2.4] 3.7 [2.9-6.0] 0.0003 
IL-11 (ng/mL) 3.5 [2.9-4.3] 5.7 [4.7-6.4] <0.0001 
TPO (ng/mL) 2.0 [1.7-2.2] 3.0 [2.6-3.4] <0.0001 
CXCL4 (ng/mL) 0.8 [0.6-1.2] 1.4 [0.7-2.8] 0.1236 
CXCL7 (ng/mL) 0.4 [0.4-0.5] 0.73[0.4-1.7] 0.1958 
SCF (pg/mL) 47.61 [37.34 - 89.34] 45.68 [36.22 - 61.39] 0.1594 
 1324 

0
5
10
−5.0 −2.5 0.0 2.5 5.0
Principal Component 1 (26.5%)
P
rin
ci
pa
l C
om
po
ne
nt
 2
 (1
1.
7%
)  
 
  
 
 
 
  
 
Cluster 1a
Cluster 1b
Cluster 2
Parasitemia
Parasite.load PvLDH
Hb Ht
RBC
WBC Neut
NF
Lymphocytes
Platelets
MPV
TNF
IL-1a
IL-1b
IL-6
IL-8
IL-10
ICAM-1
VCAM-1 E-selectin
P.selectin
Ang-1
Ang-2
CD40L
Syndecan-1
CXCL4
CXCL7
PAI-1
VWF-A2
ADAMTS13
IL-11
TPO
SCF
GM-CSF
G.CSF L-Selectin
−1.0
−0.5
0.0
0.5
1.0
−1.0 −0.5 0.0 0.5 1.0
Principal Component 1 (26.5%)
P
rin
ci
pa
l C
om
po
ne
nt
 2
 (1
1.
7%
)
Lymphopenia
Thrombocytopenia
2
4
6
contribution
EC activation
Thrombopoiesis
Total biomass
B
0
5
10
−5.0 −2.5 0.0 2.5 5.0
Principal Component 1 (26.5%)
P
rin
ci
pa
l C
om
po
ne
nt
 2
 (1
1.
7%
)  
 
Cluster 1
Cluster 2
jaccard_index
cluster 1: 0.903
cluster 2: 0.860
ln 1000/1000
wss = 1122.0
A
C


 A B
ICAM.1
VCAM.1
E.selectin
P.selectin
Ang.2
CD40L
PAI.1
VWF.A2
Syndecan.1
catsmatrix_1 10.500.51
cats cont high low
ICAM.1
VCAM.1
E.selectin
P.selectin
Ang.2
CD40L
PAI.1
VWF.A
Syndecan.1
catsm
at
rix
_1
10.
5
00.
5
1
ca
ts c
on
t
hi
gh
lo
w
EC activation
Procoagulation
Glycocalix 
breakdown
E.
se
le
ct
in
P.
se
le
ct
in
An
g.
2
C
D
40
L
PA
I.1
VW
F.
A2
Sy
nd
ec
an
.1
ca
ts
matrix_1
1
0.5
0
0.5
1
cats
cont
high
low
E.
se
le
ct
in
P.
se
le
ct
in
An
g.
2
CD
40
L
PA
I.1
VW
F.
A2
Sy
nd
ec
an
.1
ca
ts
matrix_1
1
0.5
0
0.5
1
cats
cont
high
low
E
.s
el
ec
tin
P
.s
el
ec
tin
A
ng
.2
C
D
40
L
PA
I.1
V
W
F.
A
2
S
yn
de
ca
n.
1
ca
ts
matrix_1
1
0.5
0
0.5
1
cats
cont
high
low
E.
se
le
ct
in
P.
se
le
ct
in
An
g.
2
C
D
40
L
PA
I.1
VW
F.
A2
Sy
nd
ec
an
.1
ca
ts
atrix_1
1
0.5
0
0.5
1
cats
cont
high
low
z-score
Cluster group
Vivaxlow
Vivaxhigh
Control
ICAM-1
VCAM-1
E-selectin
P-selectin
Ang-2
CD40L
PAI-1
VWF-A2
Syndecan-1
il1
a il8
ic
am
1
an
g.
1
an
g.
2
ad
am
ts
13
en
os
sy
nd
ec
an
.1
ve
gf
matrix_2
1
0.5
0
0.5
1
Control Vivaxlow z-score
EC activation
Procoagulation
EC dysfunction
EC damage
Vivaxhigh
IL1A
IL8
ICAM1
ANG1
ANG2
ADAMTS13
NOS3
SDC1
VEGF
0 3 6 9
0.0
0.5
1.0
1.5
Time (hrs)
N
or
m
al
iz
ed
 re
si
st
an
ce
Mock
Control
lowVivax
Vivaxhigh
C
FSC-A
IC
A
M
-1
V
C
A
M
-1
mIgG1 (Isotype)
ControlMockUnstained Vivaxlow Vivaxhigh
47.4%
18%
43.5% 39.7% 85%
27.7% 23.3% 49%
10 0 10 1 10 2 10 3 10 4 10 5
Alexa Fluor 488-A
0
200
400
600
Co
un
t
200
400
600
Co
un
t
Sample Name
10 0 10 1 10 2 10 3 10 4 10 5
Alexa Fluor 488-A
0
200
400
600
Co
un
t
10 0 10 1 10 2 10 3 10 4 10 5
0
200
400
600
Co
un
t
ICAM-1
VCAM-1
D
Specimen_ICAM_B12_B12_023.fcs 
Specimen_ICAM_B7_B07_018.fcs 
Specimen_ICAM_B5_B05_016.fcs 
Specimen_ICAM_B2_B02_013.fcs 
Specimen_IgG1_E1_E01_048.fcs 
Mock
Control
lowVivax
Vivaxhigh
Isotype
Specimen_ICAM_B12_B12_023.fcs 
Specimen_ICAM_B7_B07_018.fcs 
Specimen_ICAM_B5_B05_016.fcs 
Specimen_ICAM_B2_B02_013.fcs 
Specimen_IgG1_E1_E01_048.fcs 
Mock
Control
lowVivax
Vivaxhigh
Isotype
Control
Vivaxlow
Vivaxhigh
Mock
0
20
40
60
0
100
%
 IC
A
M
-1
+  c
el
ls
p < 0.0001
p < 0.0001
0
1000
2000
3000
4000
IC
A
M
-1
 (M
FI
) p < 0.0001
p < 0.0001
Vivaxlow Vivaxhigh
IC
A
M
/D
A
P
I
V
C
A
M
/D
A
P
I
0
20
40
60 p < 0.0001p < 0.0001
%
 V
C
A
M
-1
+  c
el
ls
0
100
200
300
400
500 p < 0.0001
p < 0.0001
V
C
A
M
-1
 (M
FI
)
0
0.02
0.04
0.06Total parasite biomass
Peripheral parasitemia
p-value
−1 −0.8 −0.6 −0.4 −0.2 0 0.2 0.4 0.6 0.8 1
H
b
H
t
R
B
C
L
ym
ph
oc
yt
es
P
la
te
le
ts
Le
uk
oc
yt
es
N
eu
tro
ph
ils
IL
-1
b
A
ng
-1
P
A
I-1
TN
F
G
-C
S
F
L-
se
le
ct
in
IL
-1
1
E
-s
el
ec
tin
TP
O
P
-s
el
ec
tin
IC
A
M
-1
C
D
40
L
P
ar
as
ite
m
ia
IL
-1
a
P
ar
as
ite
 lo
ad
A
ng
-2
V
W
F-
A
2
IL
-6
IL
-8
P
vL
D
H
V
C
A
M
-1
Ht
RBC
Lymphocytes
Platelets
Leukocytes
Neutrophils
IL-1b
Ang-1
PAI-1
TNF
G-CSF
L-selectin
IL-11
E-selectin
TPO
P-selectin
ICAM-1
CD40L
Parasitemia
IL-1a
Parasite load
Ang-2
VWF-A2
IL-6
IL-8
PvLDH
VCAM-1
Syndecan-1
Module 1
Module 1/2
Module 1/2
Module 1
Module 3
Module 2
Module 3
Module 3
Healthy donors
negative correlation
positive correlation
RBC
TNF-a
E-selectin
Hemoglobin
VWF-A2
IL-1b
IL-11
TPO
IL-6
IL-8
Ang-1
Platelets
CXCL7
Lymphocytes
Syndecan-1
CXCL4
Ang-2
L-Selectin
P-selectin
Hematocrit
Neutrophils
ICAM-1
PAI-1
IL-1a
VCAM-1
CD40L
G
-C
S
F
P
-s
el
ec
tin
A
ng
-1
IL
-1
b
PA
I-1
TN
F
IL
-6
IL
-8
IC
A
M
-1
R
B
C
L-
se
le
ct
in
C
D
40
L
H
em
at
oc
rit
IL
-1
a
H
em
og
lo
bi
n
S
yn
de
ca
n-
1
V
C
A
M
-1
P
la
te
le
ts
N
eu
tro
ph
ils
Le
uk
oc
yt
es
V
W
F-
A
2
E
-s
le
ct
in
Ly
m
ph
oc
yt
es
A
ng
-2
IL
-1
1
TP
O
IL-1b
G-CSF
RBC
Ang-2 Hemoglobin
Hematocrit
TPO
VCAM-1
Lymphocytes
Neutrophils
E-selectin
Syndecan-1 Platelets
IL-8
TNF-a
Ang-1
IL-10
CXCL4
PAI-1
L-Selectin
VWF-A2
CXCL7
IL-6
ICAM-1
IL-1a
IL-11
P-selectin
CD40LPvLDH
!"#$%&'(')"*+),- ./(0&012(31*&$"*-
1('#&-)(.("-2$(.'-)3/45#
6'5#&-)(.("-2 !#/"&(47&-"-8"9:;<=->-?-:;:@A
4#5/,+B#-)(""#./,+(4
>(&+,+B#-)(""#./,+(4
Fold change
Myelopoiesis/EC activation
EC activation and anemia
EC activation and glycocalix breakdown/
Lymphopenia and thrombocytopenia
Module 1
Module 3
Module 2
P. vivax patients
4
0
1
A
B C
D Syndecan-1
yes no
IL-6
 
> 33.37
 
 > 5706.82
yes no
Syndecan-1 Platelets
 
> 4940.9yes no
Vivaxlow
   (2.0)
Leukocytes 
> 2.1yes no
Vivaxhigh
   (7.0)
Vivaxlow
   (1.0)
Vivaxhigh
   (9.0)
< 50yes no
Vivaxhigh
    (7.0)
Vivaxlow
    (1.0)









